Hologic, Inc. (NASDAQ:HOLX) Holdings Decreased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale cut its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,482,871 shares of the medical equipment provider’s stock after selling 75,169 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.64% of Hologic worth $109,664,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. Innealta Capital LLC acquired a new position in Hologic in the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic in the first quarter worth $37,000. Mather Group LLC. acquired a new stake in Hologic in the first quarter worth $48,000. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Hologic by 24.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares during the period. Finally, Toth Financial Advisory Corp grew its position in shares of Hologic by 81.1% during the first quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $81.15 on Friday. The company has a 50-day moving average of $80.20 and a 200-day moving average of $76.83. The firm has a market cap of $18.85 billion, a price-to-earnings ratio of 41.40, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 earnings per share. Analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. StockNews.com upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Evercore ISI raised their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Insiders Place Their Bets

In related news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total transaction of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last ninety days. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.